-
Product Insights
New![]()
SG 4720 Mbada Mine
The SG 4720 Mbada Mine is a diamond mine in Zimbabwe. It is currently in operation. Empower your strategies with our SG 4720 Mbada Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to...
-
Product Insights
New![]()
SG Peyrissan Solar PV Park
SG Peyrissan Solar PV Park is a solar PV project located in Nouvelle-Aquitaine, France. The project is owned and developed by ENGIE Green France SAS. The project came online in 2016. Empower your strategies with our SG Peyrissan Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections...
-
Company Insights
New![]()
Innovation and Patenting activity of SGS SA Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of SGS SA Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Company Insights
New![]()
Innovation and Patenting activity of SG Micro Corp Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of SG Micro Corp Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
New![]()
Innovation and Patenting activity of SG Holdings Co Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of SG Holdings Co Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SG-2501 in Refractory Multiple Myeloma Drug Details: SG-2501 is under development for the treatment of hematological...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Relapsed Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SG-2501 in Relapsed Multiple Myeloma Drug Details: SG-2501 is under development for the treatment of hematological...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Primary Systemic Amyloidosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SG-2501 in Primary Systemic AmyloidosisDrug Details: SG-2501 is under development for the treatment of hematological tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SG-2501 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: SG-2501 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Chronic Lymphocytic Leukemia (CLL)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SG-2501 in Chronic Lymphocytic Leukemia (CLL) Drug Details: SG-2501 is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.